Objective: The aim of this study was to assess risks and benefits of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) in postmenopausal Chinese women.
M enopausal hormone therapy (MHT) affects many aspects of postmenopausal women's health, including coronary heart disease (CHD), cancer risk, thromboembolic risk, and bone loss. The Women's Health Initiative (WHI) was a large randomized controlled trial (RCT) that examined risks and benefits of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) in healthy, predominantly white women. WHI trial and follow-up data do not support an overall benefit of the use of MHT in this population, 1,2 but the generalizability of these data across racial and ethnic groups has not been demonstrated.
The risk-benefit ratio of MHT may differ by race and ethnicity. US populationYbased data demonstrate significantly lower underlying cancer and heart disease risks in Asian Americans compared with whites. Of all racial and ethnic groups in the United States, Asian Americans have the lowest incidence of and mortality from all cancers combined. 3 Heart disease risk is also lower in Asian Americans; 2004 age-adjusted death rates from heart disease were 216 per 100,000 for whites compared with 118 per 100,000 for Asian Americans. 4 Based on these observations, we hypothesized that the risks and benefits of MHT in Asian women may be different from those in white women. Specifically, we sought to determine whether CEE and MPA exposure or CEE-only exposure in postmenopausal Chinese women increases the risks of cardiovascular disease and breast cancer using data from the Taiwan National Health Insurance Research Database (NHIRD), a population-based health claims database. By examining the impact of these MHT regimens on cardiovascular disease, cancer, fractures, and death, we tested whether CEE and MPA exposure or CEE-only exposure yields a favorable risk-benefit ratio.
METHODS

Study design
The retrospective cohort study was designed to incorporate a similar study time frame, inclusion and exclusion criteria, and treatment protocol as the WHI RCT (Table 1) . 5 The study was approved by the institutional review boards of the University of Pennsylvania and University of California, San Diego.
Data source
The National Health Insurance (NHI) of Taiwan has provided comprehensive healthcare coverage for 99% of Taiwan's 22 million people, 98% of whom are Han Chinese, since 1995. 6 Since January 1997, NHI claims data including all outpatient care, inpatient care, and prescription drug use have been captured. The International Classification of Diseases (ICD), 9th Revision, Clinical Modification codes were used to classify medical diagnoses. From these data, the NHIRD research cohort was created. This research cohort comprised 1 million participants randomly sampled from the entire population. For these 1 million individuals, claims data from January 1, 1997, to December 31, 2007, have been incorporated into the deidentified research dataset used in this study.
The NHI formulary was searched for all estrogen (E)-or progesterone-containing drugs. After identifying the compounds used for MHT, all MHT prescriptions between June 1, 1997, and December 31, 2007 , that were filled by potential eligible participants were extracted to assign exposure status.
Study population
Women were potentially eligible for the study if they reached age 50 years and were younger than 80 years during the enrollment interval (June 1, 1997 1, , to May 31, 2000 . This interval was selected to coincide with the onset of NHIRD data capture and to close before the reporting of WHI data. Women older than 50 years were considered to be postmenopausal. 7 Participants were selected based on the algorithm in Figure 1 . The same inclusion and exclusion criteria except for exposure status were applied to exposed and unexposed participants to minimize selection bias. Potential eligible participants who filled at least two monthly prescriptions within 3 continuous months during the enrollment interval were categorized as exposed to MHT. For each MHT exposed participant, the first date when the MHT prescription was filled was deemed her study enrollment date. Two MHT exposure groups were selected based on prescription data. Those who filled prescriptions for daily CEE (0.625 mg daily) and MPA (5 mg daily) were considered exposed to E + progestin (P) MHT; participants who filled prescriptions for only CEE (0.625 mg daily) and no P were considered exposed to E-only MHT. For E-only MHT participants, hysterectomy status could not be reliably ascertained in this dataset because surgical procedures before 1997 were not captured. Women who filled prescriptions for other types of MHT regimens, including other doses of CEE and MPA, other estrogens and progesterones, other delivery routes (transdermal, vaginal, IM), during the recruitment interval were excluded from this analysis (57%, n = 9,502). Unexposed participants were randomly selected from the remainder of the cohort. Matched by date of birth within 5 years, two age-matched unexposed participants were randomly selected for each exposed participant and designated the 
Outcomes
For each study participant, outcome events that occurred after the enrollment date were identified by ICD-9 codes. The primary outcomes were CHD (MI and CHD death) and invasive breast cancer. CHD deaths were defined as death occurring within 28 days of hospitalizations when MI diagnosis was given. The global index was a composite outcome summarizing the earliest occurrence of breast cancer, stroke, PE, endometrial cancer, colorectal cancer, hip fracture, or death. 1 Home deaths were not captured in the NHIRD. As the Taiwan national death index is not deidentified, it was not possible to link the NHIRD participants with the public death records.
Statistical analysis
The primary analysis used time-to-event methods. Participants were classified as exposed (E + P MHT or E-only MHT) or unexposed (E + P MHT unexposed or E-only MHT unexposed). Akin to the intention-to-treat (ITT) analysis in an RCT, time to outcomes was calculated regardless of length of MHT exposure, dropout of MHT, or drop-in to MHT. 5 In this analysis, the follow-up period of each participant was defined from the participant's enrollment date to the date of the respective outcome diagnosis, death, loss of NHI coverage, or December 31, 2007, whichever was the earliest. After determining that the assumptions of proportional hazards were met, Cox proportional hazard ratios (HRs) and 95% CIs were estimated for each primary outcome as well as the global index.
Prespecified secondary analyses were performed. First, the adjusted association between hormone exposure and each outcome was determined using multivariable Cox models while controlling for confounding. Covariates ( Table 2 ) that are clinically known confounders or that changed the crude HR by more than 10% were included in multivariable models. 8 Second, we analyzed the effect of E + P or E-only MHT on participants who were 55 years or younger at study entry because the effect of hormones on outcomes may be modified by age or years since menopause. 9 In this analysis, the same procedures as in the primary analysis were undertaken for the 30% of the study population that met these age criteria.
Finally, an as-treated analysis was performed to consider the duration of hormone use and dropout and drop-ins. Unexposed participants were considered drop-ins when they fulfilled the inclusion criterion for exposure to MHT: filling two monthly prescriptions of CEE 0.625 mg within 3 months. For the drop-ins, the date of the first of two prescriptions was considered their stop point. Exposed participants who had a gap of at least 6 months of no filled hormone prescriptions were considered dropouts. Six months after the last prescription was considered the stop point. Unexposed participants who were matched to the dropouts were also assigned the same stop point if they had not experienced an outcome, death, or loss of NHI coverage by the stop point date. The as-treated analysis encompassed all participants but censored event histories after stop points in this subset of individuals.
Sample size was determined by the number of eligible women in the enrollment interval (1997) (1998) (1999) (2000) . A priori power calculations assumed an annualized incidence of breast cancer to be 0.21% in unexposed women (30% lower than reported in the WHI population). Based on 5,000 E + P MHT users and 10,000 E + P unexposed participants, the study was powered to detect a relative risk of breast cancer of 2.5 or more with 80% power and > error of 0.05. Assuming an annualized incidence of 0.15% for CHD in unexposed women (50% lower than reported in the WHI population), the study was powered to detect a relative risk of 2.9 or more.
RESULTS
A total of 16,045 study participants were in the final dataset: 4,712 participants were exposed to E + P MHT, and 1,208 participants were exposed to E-only MHT ( Fig. 1) . For E + P MHT exposed participants, there were 8,070 E + P MHT unexposed controls; for E-only MHT exposed participants, there were 2,055 E-only unexposed controls. During the study period, the number of participants lost to follow-up was small (n = 551, 3.4%).
Baseline characteristics of study participants are summarized in Table 2 . At study entry, mean (SD) ages were 58.2 (6.3) years for E + P MHT participants and 58.9 (6.2) years for E + P unexposed participants. Mean (SD) ages were 59.2 (6.9) years for E-only MHT participants and 59.7 (6.7) years for E-only unexposed participants. Baseline prevalence of risk factors for cardiovascular disease was low. Compared with unexposed participants, MHT participants were more likely to have a history of hypertension, hypercholesterolemia, statin use, and aspirin use. Participants exposed to E-only MHT were also more likely to be treated for diabetes than E-only unexposed participants. Obesity and smoking were rarely identified by ICD-9 codes. Overall, the median durations of exposure (range) in the E + P and E-only groups were 6.9 (2-117) and 9 (2-124) months, respectively. Median follow-up was 9.2 years and similar among all groups.
Primary ITT analysis
The overall rates of cardiovascular disease outcomes were low (Tables 3 and 4 ; Fig. 2A, B ). The combined rates of experiencing an acute MI or a CHD death were not statistically significantly different between women exposed to MHT and unexposed women. The rate was 7 per 10,000 person-years in the E + P MHT group, compared with 10 per 10,000 personyears in the unexposed group (HR, 0.76; 95% CI, 0.49-1.15). For E-only MHT, the combined rate was 9 per 10,000 personyears in the exposed and 10 per 10,000 person-years in the unexposed (HR, 0.85; 95% CI, 0.39-1.81) groups. E + P MHT use was associated with a 50% higher rate of breast cancer (36 vs 24 per 10,000 person-years; HR, 1.48; 95% CI, 1.20-1.83). E-only MHT also seemed to be associated with a higher rate, but this did not reach statistical significance (HR, 1.44; 95% CI, 0.99-2.10, Tables 3 and 4 ; Fig. 2C , D).
Among global index events, E + P exposure was associated with 39% lower stroke rates. In E + P MHT participants, the rate was 41 per 10,000 person-years, compared with 65 in unexposed participants (HR, 0.62; 95% CI, 0.53-0.74; Table 3 , Fig. 2E ). The rates of stroke were similar between E-only MHT and E-only unexposed participants (69 vs 71 per 10,000 personyears; HR, 1.02; 95% CI, 0.77-1.35; Table 4 , Fig. 2F ).
Rates for PE and DVT were low (Tables 3 and 4 , Fig. 2G , H). MHT exposure was not associated with combined thromboembolic rates. However, the rate of DVT was almost threefold higher in the E-only MHT group than in the E-only unexposed group (HR, 3.89 [1.60-9.46]). E + P exposure was associated with lower rates of colorectal cancer (5 vs 9 per 10,000 person-years; HR, 0.58; 95% CI, 0.36-0.93; Table 3 , Fig. 2I ). E-only MHT was not associated with colorectal cancer (HR, 0.99; 95% CI, 0.39-2.51; Table 4 , Fig. 2J ). A higher rate of endometrial cancer was observed with E + P use but not with E-only use ( Tables 3 and 4 ). E + P MHT participants had a twofold increased risk (9 vs 4 per 10,000 person-years; HR, 2.15 [1.33-3.47]). For E-only MHT participants, the HR was 1.41 (95% CI, 0.61-3.28).
Total cancer incidence was 24% higher in E + P MHT participants than in E + P unexposed participants (181 vs 146 per 10,000 person-years; HR, 1.26; 95% CI, 1.15-1.38). In addition, cancer incidence was 44% higher in E-only MHT participants than in unexposed participants (237 vs 165 per 10,000 personyears; HR, 1.59 [1.35-1.87]; Fig. 2K, L) .
Lower rates of vertebral and hip fractures were associated with E + P MHT use (26 vs 34 per 10,000 person-years; HR, 0.72; 95% CI, 0.58-0.90), but fracture rates were not different by E-only exposure (37 vs 32 per 10,000 person-years; HR, 1.14; 95% CI, 0.77-1.70; Fig. 2M, N) .
Mortality was significantly lower in E + P participants than in unexposed participants (36 vs 66 per 10,000 person-years; HR, 0.54; 95% CI, 0.45-0.64; Fig. 3A) . The E-only MHT group had a similar rate of death as the unexposed group (62 vs 70 per 10,000 person-years; HR, 0.92; 95% CI, 0.69-1.23; Fig. 3B ).
The global index composite outcome showed that E + P MHT was associated with decreased event rates (150 vs 189 per 10,000 person-years; HR, 0.79; 95% CI, 0.72-0.87; Table 3 , Fig. 3C ). In the E-only analysis, the global index was not associated with E-only MHT exposure (HR, 1.09 [0.92-1.28]; Table 4 , Fig. 3D ).
Adjusted analysis
Multivariable Cox models for each outcome were generated to adjust for age, hypercholesterolemia, hypertension, statin use, aspirin use, and antidiabetes drug use. Given the low incidence of obesity (0.04%) and smoking (0%) diagnoses, they were not included in the adjusted models. The direction and magnitude of HRs in the adjusted models were similar to the primary analysis (Tables 3 and 4 ). with a significantly lower rate of MI events (HR, 0.26; 95% CI, 0.07-0.90), an observation that remained significant after adjustment for confounders. The reduction in stroke, reduction in death, increase in breast cancer, and reduction in global index events with E + P MHT exposure remained in this analysis.
In the E-only analysis, breast cancer and any cancer rates remained higher in the exposed than in the unexposed group.
As-treated analysis
Tables 7 and 8 reflect estimates from the as-treated analysis. Eight percent of unexposed participants (n = 808) became drop-ins during the study. Overall, the duration of follow-up was shortened with censoring at dropout or drop-in, rendering fewer events. No acute MI or CHD death events occurred in E + P MHT participants, whereas 9 events per 10,000 personyears were observed in unexposed participants. In the E + P analysis, breast cancer rates were not significantly increased (HR, 0.96; 95% CI, 0.63-1.46), and colon cancer rates were not significantly decreased (HR, 0.50; 95% CI, 0.21-1.16).
In the E-only analysis, breast cancer rates were not increased in MHT users (HR, 0.79; 95% CI, 0.40-1.58). However, the global index demonstrated significantly higher risk of outcomes associated with E-only MHT use (HR, 1.24; 95% CI, 1.05-1.47]).
HRs for other outcomes remained similar to the ITT analysis. Lower stroke (HR, 0.51; 95% CI, 0.34-0.77) and death rates (HR, 0.46; 95% CI, 0.36-0.58) remained significantly associated with E + P MHT. Higher endometrial cancer rate was observed in the E + P exposure group (HR, 3.45; 95% CI, 1.56-7.63).
DISCUSSION
In postmenopausal Chinese women, the risk of coronary heart disease was low and was not associated with exposure to MHT using CEE with or without MPA. A higher rate of breast cancer may be associated with CEE and MPA exposure. The global index demonstrated a significantly decreased event rate associated with CEE and MPA exposure but not with CEE-only exposure.
Absolute rates of acute MI and CHD death were low but similar among exposed and unexposed women, despite both hormone exposure groups having more risk factors for cardiovascular outcomes at baseline. The low rates may reflect the younger age of study participants as well as the underlying Asian population. Among women younger than 55 years, combination MHT exposure was associated with lower rates of MI and CHD death. In contrast with the WHI and Heart and Estrogen/Progestin Replacement Study, 10 no increased risk of CHD outcomes was observed at initiation. Although the findings are novel and contribute to limited published data on CHD and MHT in this population, it should be noted that the low event rates limited the study power and ability to demonstrate statistical certainty. In addition, some known confounders such as diet, body size, and physical activity could not be adequately assessed in this dataset.
Increased breast cancer risk was associated with CEE with MPA use. The absolute increases were 12 more breast cancers per 10,000 person-years for E + P MHT exposure. Similar to WHI data, the rates in unexposed, and E + P MHT groups were similar in the first 4 years but diverged thereafter. However, this effect disappeared in the as-treated analysis, which censored event history 6 months after drug discontinuation. The as-treated result may reflect low power to detect events once follow-up was limited or there was a long latency between HT exposure and breast cancer that was not captured by restricting follow-up time, The data comparing the E-only MHT group with the unexposed group did not demonstrate a protective effect. This is consistent with previous cohort data including a comprehensive meta-analysis 11 and the WHI observational arm. 12 A constraint of this dataset in studying breast cancer risks was the inability to control for some risk factors such as parity, age at first birth, body size, family history, and age at menopause.
Lower stroke risk was consistently associated with combination MHT, despite higher baseline risks of hypertension and hypercholesterolemia in these women. Most previous data suggest increased risk of strokes regardless of age. 10,13<15 To date, there are no other data on risk of stroke with MHT exposure in postmenopausal Asian women. Moreover, a recent study supports the validity of the stroke diagnosis in the NHIRD dataset. 16 Although our results should be interpreted with caution and may be caused by uncontrolled confounding, the findings are consistent with the hypothesis of differential risks and benefits of MHT by population and warrants further future investigation.
Colorectal cancer rates were lower in E + P participants compared with E + P unexposed participants. Our data are consistent with both the WHI and observational studies of E + P. Endometrial cancer risk was higher among MHT exposed women with or without MPA. In the CEE-only group, this risk probably resulted from unopposed estrogen exposure in women with a uterus. It is unclear why the combined MHT group also had a significantly higher risk of uterine cancer given the evidence of filled progesterone prescriptions, but it is a limitation of administrative databases that compliance cannot be measured. Nonetheless, these data highlight the relationship between estrogen alone and uterine cancer to providers and patients.
Thromboembolic disease risks were very low and probably reflect shorter MHT exposure. An increased risk of DVT and PE was expected with any estrogen exposure but was observed only in the E-only group compared with the unexposed group. Through the entire follow up, the rate of DVT and PE for the E + P group never deviated from that of controls.
Fracture risks in the population were similar to self-reported data in postmenopausal Chinese women. 17 HRs in both MHT treatment groups support the protective effect of estrogen exposure against fractures, but only the combination MHT group had significantly lower fracture rates. The lack of significant association with E-only MHT may be a consequence of limited power.
Death rates were similar in the E-only MHT and unexposed groups but significantly lower in the E + P MHT group compared with the E + P unexposed group. The decreased death rate cannot be explained by known baseline comorbidities or the sum of all major outcomes. Because deaths captured in the NHIRD do not account for deaths that occur outside the hospital, it is possible that the rate of home deaths differed by MHT exposure groups. In the WHI CEE and MPA or CEE-only trials, all-cause mortality was similar between exposed and unexposed women, but a reanalysis of the data demonstrated a reduced relative risk (0.7 [0.51-0.96]) among younger women from 50 to 59 years of age. 9 Our population of younger Asian women supports this observation.
MHT remains a controversial treatment for which there are very limited data in Asian women. This study is the largest to date in this population and offers two important advantages. It is population-based because national health insurance covers 99% of the population and generalizable. Second, the dataset captures drug use and outcomes comprehensively because of the broad scope of medications and services covered by NHI. In comparison, a multicenter RCT of 1,100 Asian women evaluated the efficacy of three doses of combination CEE/MPA (0.625/2.5, 0.45/1.5, 0.3/1.5) for the relief of vasomotor and vaginal atrophy symptoms, but the study is limited by sample size and short follow-up. 18 Finally, the study was able to examine a number of clinically important outcomes in postmenopausal Asian women.
There are several additional considerations in interpreting the data from this observational study. Because of the limited sample size, there may be effects of MHT that we were underpowered to detect, and the CIs of many of the effect estimates are relatively wide. Furthermore, compared with the WHI, the duration of hormone exposure in this study was short, and the NHIRD population was younger. Shorter hormone exposure may reflect limited adherence or the practice pattern in this population. Although these data are generalizable to the large number of postmenopausal Taiwanese women, the difference in duration of exposure limits the comparisons of the two studies.
Because randomization did not occur, selection bias and uncontrolled confounding are limitations of the study design. Unexpectedly, women in this general population who received hormone therapy had more comorbidities at baseline, which may bias estimates on outcomes such as CHD toward the null. This may be attributed to the timing of the NHIRD study entry, when MHT was commonly prescribed for secondary prevention of cardiovascular disease. In adjusted analyses, we accounted for known confounding and report that HRs did not substantially change. However, as discussed, there are other confounders that could not be accounted for in this dataset. One example is exposure to dietary phytoestrogens. Soy products are common in the diet of this population, but food intake is not a part of the data acquired by the NHIRD. There are neither reported data on the intake of isoflavones in postmenopausal Taiwanese women nor data on whether this intake varies with use of MHT. Therefore, we were unable to control for this factor.
Third, using a deidentified claims database relies on ICD-9 diagnostic and procedure codes. The two major limitations to this approach are that clinic and hospital coding may overcount or undercount the number of true diagnoses and contribute to information bias. Moreover, because the dataset is deidentified, we were unable to perform traditional validation steps such as verifying diagnoses through medical chart review of a subset of participants or have diagnoses undergo adjudication. This limitation was approached by additional analyses restricting outcome diagnoses to those with a corroborating clinical procedure or prescription (data not shown). Hazards did not significantly change in direction or magnitude. Finally, exclusion criteria were limited to diagnoses in the 6 months before study entry because the beginning of data collection for the NHIRD preceded the enrollment period by a short interval. However, because medications required monthly physician visits and prescriptions, it is less probable that significant exclusionary diagnoses were missed.
CONCLUSIONS
In postmenopausal Chinese women, the risks of cardiovascular disease outcomes were low. In the setting of limited exposure to CEE 0.625 mg with and without MPA 5 mg, the rates of MI and CHD death did not differ with MHT exposure. E + P MHT may be associated with an increased rate of breast cancer. Overall, women who were exposed to combination MHT had lower rates of global index events. Although many outcomes were similar to those reported by the WHI, there were notable differences in some absolute risks and outcome rates that warrant further investigation in this population.
